Novo Nordisk
NVO
1,663 hedge funds and large institutions have $30.2B invested in Novo Nordisk in 2024 Q4 according to their latest regulatory filings, with 208 funds opening new positions, 600 increasing their positions, 641 reducing their positions, and 291 closing their positions.
6% more call options, than puts
Call options by funds: $1.28B | Put options by funds: $1.21B
0.08% more ownership
Funds ownership: 9.89% → 9.97% (+0.08%)
6% less repeat investments, than reductions
Existing positions increased: 600 | Existing positions reduced: 641
7% less funds holding
Funds holding: 1,784 → 1,663 (-121)
24% less capital invested
Capital invested by funds: $39.7B → $30.2B (-$9.51B)
29% less first-time investments, than exits
New positions opened: 208 | Existing positions closed: 291
49% less funds holding in top 10
Funds holding in top 10: 63 → 32 (-31)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GQG Partners
Ft. Lauderdale,
Florida
|
+$601M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$319M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$285M |
| 4 |
Two Sigma Investments
New York
|
+$199M |
| 5 |
ClearBridge Investments
New York
|
+$173M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$855M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$350M |
| 3 |
Morgan Stanley
New York
|
-$234M |
| 4 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
-$194M |
| 5 |
MIF
Mediolanum International Funds
Dublin 1,
Ireland
|
-$98.8M |
NVO Hedge Fund Activity: Q4 2024 in Review
1,663 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2024, worth a combined $30.2B — down 24% from $39.7B a quarter earlier.
Sellers outnumbered buyers: 291 funds closed out of NVO and 208 opened new positions — a net loss of 83 holders — while 641 trimmed existing stakes and 600 added.
The largest buyer was GQG Partners, adding an estimated $601M. The largest seller was Fidelity Investments, cutting an estimated $855M.
- 1,663 institutional investors held Novo Nordisk (NVO) as of Q4 2024, down from 1,784 in Q3 2024.
- Funds reported $30.2B of Novo Nordisk stock for Q4 2024, down 24% quarter-over-quarter.
- 208 funds opened new Novo Nordisk positions in Q4 2024 and 291 closed out, a net change of -83 holders.
- The largest Novo Nordisk buyer in Q4 2024 was GQG Partners, an estimated $601M added.
- The largest Novo Nordisk seller in Q4 2024 was Fidelity Investments, an estimated $855M sold.
Based on aggregated 13F filings for Q4 2024.